<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228942</url>
  </required_header>
  <id_info>
    <org_study_id>15248</org_study_id>
    <nct_id>NCT01228942</nct_id>
  </id_info>
  <brief_title>A Prospective Trial of COXEN Chemotherapy Prediction</brief_title>
  <official_title>A Prospective Trial of COXEN Chemotherapy Prediction in Persistent and Recurrent Ovarian, Fallopian Tube, and Peritoneal Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the COXEN algorithm, using the diagnostic device&#xD;
      Affymetrix GeneChip, is able to predict which chemotherapies will be best for treatment of&#xD;
      recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current proposal seeks to apply and extend this novel genomic prediction technique to&#xD;
      finding better chemotherapeutic options for recurrent ovarian cancer using individual&#xD;
      patients' gene-expression signatures of chemosensitivity. The utility of the COXEN technique&#xD;
      has been validated and found to accurately predict 1) the chemosensitivity of an independent&#xD;
      panel of 40 bladder cancer cell lines; 2) activity of each of the &gt;45K candidate compounds in&#xD;
      the NCI-60 drug screening database, which resulted in the identification of a&#xD;
      highly-effective novel compound for bladder cancer and patients' responses and survival on 12&#xD;
      historical clinical trials of combination chemotherapy. In particular, the GEMs of breast&#xD;
      cancer can be used to stratify both clinical response and overall patient survival with a&#xD;
      striking difference between the predicted responders vs. predicted non-responders in 5&#xD;
      independent chemotherapeutic trials of breast cancer. The next step is to test the prediction&#xD;
      model in recurrent ovarian cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding/resources&#xD;
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>12 months</time_frame>
    <description>patient will have CT scans and CA 125 drawn to track response to chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>subject lifetime</time_frame>
    <description>patient will be tracked for life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Fallopian Tube Neoplasms</condition>
  <arm_group>
    <arm_group_label>Platinum Sensitive</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with platinum-based therapy; COXEN prediction model chooses secondary agent if doublet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Platinum resistent</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>single agent based on Coxen prediction model</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>COXEN analysis for chemotherapy prediction</intervention_name>
    <description>Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined</description>
    <arm_group_label>Platinum Sensitive</arm_group_label>
    <arm_group_label>Platinum resistent</arm_group_label>
    <other_name>Affymetrix genechip</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age greater than 18&#xD;
&#xD;
          -  diagnosis of recurrent, persistent, refractory ovarian, fallopian or primary&#xD;
             peritoneal cancer&#xD;
&#xD;
          -  tumor tissue, ascites or pleural fluid available for biopsy&#xD;
&#xD;
          -  life expectancy greater than 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with borderline or low malignant histologies&#xD;
&#xD;
          -  patients with a history of other malignancies within last 5 years&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Duska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Linda R Duska</investigator_full_name>
    <investigator_title>Medical Attending</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

